Stage III Verrucous Carcinoma of the Larynx Terminated Phase 2 Trials for DB08916 (Afatinib)

IndicationStatusPhase
DBCOND0029516 (Stage III Verrucous Carcinoma of the Larynx)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01824823Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of RecurrenceTreatment